These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 12593946)

  • 1. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice.
    Afouna MI; Fincher TK; Zaghloul AA; Reddy IK
    Int J Pharm; 2003 Mar; 253(1-2):159-68. PubMed ID: 12593946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice.
    Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; DeClercq E; El-Shattawy HH
    J Pharm Sci; 1999 May; 88(5):530-4. PubMed ID: 10229644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of correlation between skin target site free drug concentration and the in vivo topical antiviral efficacy in hairless mice for (E)-5-(2-bromovinyl)-2'-deoxyuridine and acyclovir formulations.
    Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; De Clercq E; El-Shattawy HH
    J Pharm Sci; 1998 Aug; 87(8):917-21. PubMed ID: 9687333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of in vivo topical efficacies with in vitro predictions using acyclovir formulations in the treatment of cutaneous HSV-1 infections in hairless mice: an evaluation of the predictive value of the C* concept.
    Patel PJ; Ghanem AH; Higuchi WI; Srinivasan V; Kern ER
    Antiviral Res; 1996 Mar; 29(2-3):279-86. PubMed ID: 8739606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
    Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E
    Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.
    De Clercq E; Holý A
    Antimicrob Agents Chemother; 1991 Apr; 35(4):701-6. PubMed ID: 2069375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice.
    Lee PH; Su MH; Kern ER; Higuchi WI
    Pharm Res; 1992 Aug; 9(8):979-89. PubMed ID: 1329068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model.
    Romanowski EG; Bartels SP; Gordon YJ
    Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):378-84. PubMed ID: 9950596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of acyclovir-resistant herpes simplex virus.
    Chilukuri S; Rosen T
    Dermatol Clin; 2003 Apr; 21(2):311-20. PubMed ID: 12757254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of skin target site free drug concentration (C*) to the in vivo efficacy: an extensive evaluation of the predictive value of the C* concept using acyclovir as a model drug.
    Mehta SC; Afouna MI; Ghanem AH; Higuchi WI; Kern ER
    J Pharm Sci; 1997 Jul; 86(7):797-801. PubMed ID: 9232519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of in vitro flux through hairless mouse skin of cidofovir, a potent nucleotide analog.
    Aspe E; Guy RH; Lee WA; Kennedy JA; Visor GC; Ennis RD
    J Pharm Sci; 1995 Jun; 84(6):750-4. PubMed ID: 7562417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child.
    Bryant P; Sasadeusz J; Carapetis J; Waters K; Curtis N
    Pediatr Infect Dis J; 2001 Nov; 20(11):1083-6. PubMed ID: 11734717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of skin target site acyclovir concentrations following controlled (trans)dermal drug delivery in topical and systemic treatment of cutaneous HSV-1 infections in hairless mice.
    Imanidis G; Song WQ; Lee PH; Su MH; Kern ER; Higuchi WI
    Pharm Res; 1994 Jul; 11(7):1035-41. PubMed ID: 7937545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneously applied acyclovir acts systemically in the treatment of herpetic infection in the hairless mouse.
    Bolger GT; Allen T; Garneau M; Lapeyre N; Liard F; Jaramillo J
    Antiviral Res; 1997 Aug; 35(3):157-65. PubMed ID: 9298755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs.
    Bravo FJ; Stanberry LR; Kier AB; Vogt PE; Kern ER
    Antiviral Res; 1993 May; 21(1):59-72. PubMed ID: 8391249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cidofovir use in acyclovir-resistant herpes infection.
    Martinez CM; Luks-Golger DB
    Ann Pharmacother; 1997 Dec; 31(12):1519-21. PubMed ID: 9416391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS.
    Lalezari JP; Drew WL; Glutzer E; Miner D; Safrin S; Owen WF; Davidson JM; Fisher PE; Jaffe HS
    J Infect Dis; 1994 Sep; 170(3):570-2. PubMed ID: 8077713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
    Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of 1-dodecylazacycloheptan-2-one (Azone) on the topical therapy of cutaneous herpes simplex virus type 1 infection in hairless mice with 2',3'-di-O-acetyl-9-beta-D-arabinofuranosyladenine and 5'-O-valeryl-9-beta-D-arabinofuranosyladenine.
    Shannon WM; Westbrook L; Higuchi WI; Sugibayashi K; Baker DC; Kumar SD; Fox JL; Flynn GL; Ho NF; Vaidyanathan R
    J Pharm Sci; 1985 Nov; 74(11):1157-61. PubMed ID: 4087174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acyclovir-resistant herpes: expanded access available for cidofovir gel (Forvade).
    AIDS Treat News; 1997 Feb; (No 264):5. PubMed ID: 11364104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.